American Century Companies
GTHX

American Century Companies’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

American Century Companies’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-34,648
Closed -$150K – 2979
2024
Q1 		$150K Buy
34,648
+18,267
+112% +$63.7K ﹤0.01% 2809
2023
Q4 		$50K Buy
+16,381
New +$30.8K ﹤0.01% 2846

Other funds holding GTHX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

American Century Companies's GTHX Position: Q2 2024 in Review

American Century Companies sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2024, closing a stake of 34,648 shares — an estimated $150K sold.

American Century Companies first reported a position in GTHX in Q4 2023 and held it in 2 quarters. The position peaked at $150K in Q1 2024. 88 funds tracked by Wall St. Rank hold GTHX as of Q2 2024.

  • American Century Companies reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • American Century Companies sold 34,648 G1 Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $150K.
  • American Century Companies first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2023 and held it in 2 quarters.
  • American Century Companies's G1 Therapeutics, Inc. Common Stock position peaked at $150K in Q1 2024.
  • 88 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2024.

Based on American Century Companies's 13F filing for Q2 2024, filed 7 Aug 2024.